BioMarin Pharmaceuticals on Monday said it is restricting sales of its hemophilia A gene therapy to three countries in an effort to reduce costs and help the treatment become profitable by 2025.
Switzerland’s Sonova on Tuesday introduced a hearing aid that utilizes real-time artificial intelligence to improve speech clarity from background noise, the first such product in the global market, sending its shares 5% higher.
With the late-stage win, Bayer announced that it plans to talk to regulators about seeking approval in an indication that is central to its $3 billion-plus peak sales forecast.
As part of a pipeline realignment, Bristol Myers Squibb is returning the rights to Agenus for its proprietary TIGIT bispecific antibody program and terminating their 2021 license, development and commercialization agreement.
The two companies were hit with a federal lawsuit in Maryland on Monday by the family of a woman whose tissue cells were taken from her body in the 1950s and used to fuel medical research and development.
Agencies with healthcare clients in pharmaceuticals, healthcare services, digital health apps, or health-related connected devices such as wearables should take note that the Federal Trade Commission (FTC) final rule updating its Health Breach Notification Rule (HBNR) took effect on July 29, 2024.